FIELD: medicine.
SUBSTANCE: method of the invention comprises administration of 4,4'-[fluoro(1H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile to a male patient with the total serum testosterone level of less than 400 ng/dl, at a dose of 0.001-1.0 mg weekly. The composition of the invention includes a pharmaceutical composition and instructions for administration.
EFFECT: increased testosterone levels in these patients.
19 cl, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS COMPRISING AROMATASE INHIBITOR | 2012 |
|
RU2617510C2 |
| METHOD AND PHARMACEUTICAL COMPOSITIONS FOR RELIABLE ACHIEVEMENT OF ACCEPTABLE LEVELS OF TESTOSTERONE IN SERUM | 2004 |
|
RU2354381C2 |
| PHARMACEUTICAL FORMULATIONS AND METHODS INCLUDING COMBINATIONS OF 2-ALKYLIDEN DERIVATIVES OF 9-NOR-VITAMIN D AND BISPHOSPHONATE | 2004 |
|
RU2326695C2 |
| LONG-CHAIN LIPOSBALANCED ESTERS OF TESTOSTERONE FOR ORAL DELIVERY | 2014 |
|
RU2722592C2 |
| TRANS-CLOMIPHENE DOSING REGIMEN | 2006 |
|
RU2413508C2 |
| METHOD FOR CORRECTION OF ERECTILE DYSFUNCTION CAUSED BY HYPERESTRADIOLEMIA IN MEN | 2014 |
|
RU2582273C1 |
| METHOD OF TREATING HYPOGONADOTROPIC HYPOGONADISM, NASAL SPRAY AS METHOD FOR ADMINISTERING GONADORELIN ACETATE IN TREATING HYPOGONADOTROPIC HYPOGONADISM | 2019 |
|
RU2733465C1 |
| ORAL PHARMACEUTICAL COMPOSITIONS OF TESTOSTERONE ESTERS AND METHOD FOR TESTOSTERONE SHORTAGE TREATMENT WITH THEIR USE | 2010 |
|
RU2642244C2 |
| METHOD FOR TREATMENT OF ADOLESCENT HYPOGONADOTROPIC HYPOGONADISM IN EXPERIMENT | 2020 |
|
RU2750713C1 |
| METHOD OF TREATING CHRONIC ABACTERIAL PROSTATITIS WITH SELECTIVE MODULATORS OF ESTROGEN RECEPTORS OR AROMATASE INHIBITORS | 2007 |
|
RU2480207C2 |
